Hybridan

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Your Partner for Growth

Your Partner for Growth, Hybridan

Equity Bottom-Up

<ul>
<li>Arecor Therapeutics 80.00p £29.26m (AREC.L) The biopharmaceutical Company focused on drug development and enhanced delivery in diabetes and other cardiometabolic diseases provided a business update for the 12 months ended 31 December 2025.</li>
<li>The Company continued focus on two core product areas: diabetes and oral delivery of peptides.</li>
<li>A codevelopment deal was signed in September 2025 with Sequel Med Tech to combine Arecor's ultra-concentrated, ultra-rapid-acting (500U/mL) insulin AT278 with Sequel's twist Automated Insulin Delivery (AID) system. </li>
</ul>


Arecor Therapeutics 80.00p £29.26m (AREC.L) The biopharmaceutical Company focused on drug development and enhanced delivery in diabetes and other cardiometabolic diseases provided a business update for the 12 months ended 31 December 2025.
The Company continued focus on two core product areas: diabetes and oral delivery of peptides.
A codevelopment deal was signed in September 2025 with Sequel Med Tech to combine Arecor's ultra-concentrated, ultra-rapid-acting (500U/mL) insulin AT278 with Sequel's twist Automated Insulin Delivery (AID) system. 


Hybridan Small Cap Feast: 9 February 2026

Aurrigo International

Hybridan Small Cap Feast: 9 February 2026